Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Segall Bryant & Hamill LLC

Key Points

• Segall Bryant & Hamill boosted its Neurocrine stake by 20.8% in Q3 to 54,474 shares (≈$7.65M), while institutional investors now own about 92.6% of the company.
• Neurocrine reported Q3 EPS of $1.88, missing the $2.36 consensus, even as revenue rose 28.3% YoY to $805.5M; analysts still rate the stock a "Moderate Buy" with a consensus target of $175.05 despite several recent price-target cuts.
• Insiders have been net sellers: CEO Kyle Gano sold 36,400 shares (~$4.83M) and insiders disposed of 46,966 shares worth $6.47M over the past 90 days.

Segall Bryant & Hamill LLC lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 20.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,474 shares of the company's stock after buying an additional 9,383 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.05% of Neurocrine Biosciences worth $7,647,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NBIX. 111 Capital purchased a new stake in shares of Neurocrine Biosciences during the third quarter valued at approximately $244,000. Fisher Asset Management LLC boosted its stake in shares of Neurocrine Biosciences by 8.3% in the third quarter. Fisher Asset Management LLC now owns 94,795 shares of the company's stock valued at $13,307,000 after purchasing an additional 7,255 shares during the period. Journey Strategic Wealth LLC acquired a new stake in Neurocrine Biosciences during the 3rd quarter valued at $254,000. APG Asset Management N.V. increased its stake in Neurocrine Biosciences by 0.7% during the 3rd quarter. APG Asset Management N.V. now owns 61,008 shares of the company's stock worth $8,564,000 after buying an additional 430 shares during the period. Finally, Aster Capital Management DIFC Ltd purchased a new stake in Neurocrine Biosciences during the 3rd quarter worth $49,000. Hedge funds and other institutional investors own 92.59% of the company's stock.

Neurocrine Biosciences Trading Up 1.8%

Shares of NASDAQ NBIX opened at $133.44 on Thursday. The company has a market capitalization of $13.39 billion, a price-to-earnings ratio of 28.64, a PEG ratio of 0.68 and a beta of 0.32. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $160.18. The firm has a 50-day moving average of $135.00 and a two-hundred day moving average of $140.52.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts' consensus estimates of $2.36 by ($0.48). Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The company had revenue of $805.50 million during the quarter, compared to analyst estimates of $804.21 million. During the same quarter last year, the business earned $1.69 EPS. The company's revenue for the quarter was up 28.3% compared to the same quarter last year. As a group, research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on NBIX. Truist Financial lowered their target price on Neurocrine Biosciences from $169.00 to $140.00 and set a "buy" rating for the company in a research note on Tuesday, February 17th. Wells Fargo & Company reduced their price target on Neurocrine Biosciences from $180.00 to $175.00 and set an "overweight" rating for the company in a report on Friday, February 13th. JPMorgan Chase & Co. lowered their price objective on Neurocrine Biosciences from $177.00 to $176.00 and set an "overweight" rating for the company in a research note on Tuesday, February 17th. Royal Bank Of Canada dropped their price target on shares of Neurocrine Biosciences from $180.00 to $177.00 and set an "outperform" rating for the company in a research note on Thursday, February 12th. Finally, Weiss Ratings reissued a "hold (c+)" rating on shares of Neurocrine Biosciences in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $175.05.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Leslie V. Norwalk sold 1,190 shares of the business's stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $155.09, for a total transaction of $184,557.10. Following the sale, the director directly owned 6,239 shares of the company's stock, valued at $967,606.51. The trade was a 16.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kyle Gano sold 36,400 shares of the stock in a transaction on Friday, January 16th. The shares were sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the sale, the chief executive officer owned 140,407 shares of the company's stock, valued at $18,632,008.90. The trade was a 20.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 46,966 shares of company stock worth $6,474,616. 4.80% of the stock is owned by corporate insiders.

About Neurocrine Biosciences

Neurocrine Biosciences NASDAQ: NBIX is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine's operations encompass drug discovery, clinical development and commercialization activities.

The company's lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.